However, although trastuzumab is one of the most effective targeted cancer therapies for patients with HER2-positive breast cancer, development of clinical resistance to trastuzumab has been observed in a significant number of patients undergoing adjuvant therapy 2-4, emphasizing the importance for understanding the underlying mechanisms associated with trastuzumab resistance in patients with breast cancer. Here, ERBB2 is linked to cancer.